Testosterone therapy and heart health have been debated for over a decade, and until recently the debate ran ahead of the evidence. The TRAVERSE trial, a large randomized cardiovascular safety study published in 2023, gave the clearest data yet: in middle-aged and older men with hypogonadism and existing or high cardiovascular risk, testosterone therapy did not increase the rate of major adverse cardiovascular events compared with placebo. That finding does not make testosterone risk-free, but it addresses the specific fear that has shadowed treatment since earlier, weaker studies raised alarms.

The honest framing is that TRAVERSE answered a safety question, not an enhancement question. It studied men with genuinely low testosterone and symptoms, treated to a physiologic range, under monitoring. It is not a green light for high-dose testosterone in men who do not need it. The rest of this guide explains what the trial showed, what it did not, and how the decision is made.

Key Takeaways
  • Testosterone therapy and heart health were clarified by TRAVERSE, a large randomized cardiovascular safety trial published in 2023
  • In men with hypogonadism and cardiovascular risk, testosterone did not raise the rate of major adverse cardiovascular events versus placebo
  • TRAVERSE studied treatment of diagnosed low testosterone to a physiologic range, not high-dose or performance use
  • The trial noted some other findings, including atrial fibrillation, that keep monitoring necessary
  • You pay GoodLife for the clinician who confirms the diagnosis with labs and monitors treatment; medication is billed separately by the pharmacy with no GoodLife margin

What was the concern about testosterone and the heart?

Around 2013 to 2015, a few observational studies and an FDA safety communication suggested testosterone therapy might increase cardiovascular risk. The data were limited and inconsistent, but the concern stuck, and it made both clinicians and patients cautious. What was missing was a large, randomized trial designed specifically to test cardiovascular safety in the men most likely to be affected: those with low testosterone and existing heart risk.

TRAVERSE was designed to fill exactly that gap, which is why its result carries more weight than the earlier signals that prompted the worry.

What did TRAVERSE actually find?

TRAVERSE randomized thousands of men aged 45 to 80 with hypogonadism, symptoms, and either established cardiovascular disease or high risk for it, to testosterone gel or placebo, and followed major adverse cardiovascular events. The primary result was non-inferiority: testosterone did not increase the rate of heart attack, stroke, or cardiovascular death compared with placebo. For a treatment decision, that is reassuring, because it directly tests the population where the risk was feared.

The trial also reported some secondary findings that keep clinicians attentive, including a higher rate of atrial fibrillation and some other events in the testosterone group. This is why the takeaway is not simply safe, but rather safe with monitoring, in the right patient, which is the standard our hormone optimization program applies.

Who does this evidence apply to?

TRAVERSE applies to men with a genuine diagnosis of low testosterone, confirmed on labs and matched to symptoms, treated to a normal physiologic range. It does not speak to men taking high doses to build muscle, men with normal testosterone chasing a performance edge, or testosterone obtained without monitoring. Those uses carry different risks and were not what the trial studied. The distinction between treating a diagnosed deficiency and enhancing a normal level is the whole difference between medicine and marketing.

Clinical note

Low testosterone is diagnosed with morning blood testing, usually confirmed on more than one occasion, and interpreted alongside symptoms. A single borderline result is a reason to test again, not a reason to start therapy.

How is testosterone therapy monitored?

Responsible testosterone therapy is monitored, not set and forgotten. A clinician checks the response, watches red blood cell counts because testosterone can raise them, tracks PSA and prostate health per age-appropriate guidance, and stays alert to symptoms like palpitations. The goal is a physiologic level that resolves symptoms, not the highest number possible. This ongoing oversight is the part that a membership model supports well and that a one-time prescription mill does not, as our how it works page describes.

How is this handled at GoodLife Health?

The structure is transparent. Your clinician confirms the diagnosis with morning labs, decides whether testosterone is appropriate given your cardiovascular and prostate history, prescribes and titrates to a physiologic range, and monitors your labs over time. The Foundation membership is 179 dollars a month, and the tier that adds hormone optimization is 299 dollars a month. Medication is billed separately by the pharmacy, and GoodLife takes no margin on it. The membership pays for the clinician who reads the labs and watches the heart, which is exactly the oversight the evidence assumes.

What TRAVERSE did not settle

TRAVERSE was reassuring on the specific question it was designed to answer, but it did not settle everything, and honest care means naming the limits. The trial followed men for a defined period, so it speaks to that window rather than to decades of continuous therapy. It studied men with diagnosed hypogonadism treated to a physiologic range, so it says nothing about the safety of high doses used for muscle building or performance, which remain a different and less reassuring picture.

The secondary findings are part of the reason monitoring continues. The higher rate of atrial fibrillation seen in the testosterone group, along with the known tendency of testosterone to raise red blood cell counts, means a clinician keeps watching your labs and symptoms rather than treating a normal trial result as a reason to stop paying attention. Prostate health monitoring, appropriate to your age, remains part of the plan as well.

The practical takeaway is that TRAVERSE moved testosterone therapy from under a cloud of cardiovascular fear into the category of treatments that are reasonable in the right patient with proper monitoring. It did not turn testosterone into a supplement to take casually. The men who benefit are those with a real deficiency, confirmed on labs and matched to symptoms, whose treatment is followed over time, and that combination of diagnosis and supervision is exactly what the trial assumed.

For a patient weighing the decision, the useful frame is proportionality. If you have symptomatic, lab-confirmed low testosterone, TRAVERSE means the cardiovascular fear that may have been holding you back is far weaker than the headlines of a decade ago suggested, provided treatment is monitored. If your testosterone is normal and you are considering therapy for a performance edge, the same trial offers you nothing reassuring, because it did not study that use, and the risks of pushing a normal hormone higher are real.

Frequently Asked Questions

Does testosterone therapy cause heart attacks?

The TRAVERSE trial, a large randomized cardiovascular safety study published in 2023, found that testosterone therapy did not increase major adverse cardiovascular events compared with placebo in men with low testosterone and cardiovascular risk. It is monitored because of some other findings, but the main heart-attack fear was not supported.

Who does the TRAVERSE evidence apply to?

It applies to men with a confirmed diagnosis of low testosterone and symptoms, treated to a normal physiologic range under monitoring. It does not apply to high-dose or performance use, or to men with normal testosterone.

What did TRAVERSE find besides cardiovascular safety?

The trial reported some secondary findings, including a higher rate of atrial fibrillation in the testosterone group, which is one reason ongoing monitoring is part of responsible treatment.

How is testosterone therapy monitored?

A clinician confirms the diagnosis with morning blood tests, then tracks the response, red blood cell counts, prostate health per age-appropriate guidance, and any new symptoms. The aim is a physiologic level that resolves symptoms, not the highest possible number.

Related Reading

References

  1. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med, 2023.
  2. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2018.

This article is informational only and is not medical advice. GoodLife Health is a direct primary care telehealth membership, not a pharmacy, compounder, or supplement seller, and it does not manufacture, dispense, or take title to any medication. Individual results vary. Consult a licensed clinician about your situation.